文献速递其他结缔组织病

阿巴西普治疗活动性原发干燥综合征的III期随机对照试验

Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
PubMed 文献 · Ann Rheum Dis · 2020-11-09

这项III期随机双盲安慰剂对照试验评估阿巴西普在活动性原发干燥综合征(pSS)成人患者中的疗效与安全性,主要终点第169天ESSDAI变化未达统计学显著,关键次要终点ESSPRI和刺激全唾液流率亦无显著差异,未发现新安全性信号。

要点

  • 阿巴西普每周皮下125mg治疗169天,主要终点ESSDAI变化与安慰剂无显著差异。
  • 关键次要终点ESSPRI和刺激全唾液流率均未达统计学显著。
  • 部分疾病相关生物标志物和致病细胞亚群有显著差异,但属事后分析。

核心结论

  • 阿巴西普治疗中重度pSS未显示显著临床疗效,尽管有生物学活性证据。

研究设计与样本

  • III期随机双盲安慰剂对照试验,纳入符合2016 ACR/EULAR标准、ESSDAI≥5且抗Ro抗体阳性的中重度pSS成人患者。
  • 187例患者随机接受每周皮下阿巴西普125mg或安慰剂至第169天,随后开放标签延伸至第365天。

主要发现

  • 第169天ESSDAI平均变化阿巴西普-3.2 vs 安慰剂-3.7,p=0.442,未达统计学显著。
  • 关键次要终点ESSPRI(p=0.337)和刺激全唾液流率(p=0.584)均无显著差异。
  • 其他临床和患者报告结局亦未见阿巴西普优于安慰剂。
  • 事后分析显示阿巴西普在部分疾病相关生物标志物(包括IgG、IgA、IgM-rheumatoid factor)和致病细胞亚群方面与安慰剂有显著差异。
  • 未发现新的安全性信号。

关键数值与推荐

  • 纳入标准:2016 ACR/EULAR分类标准的中重度pSS,ESSDAI≥5,抗SSA/抗Ro抗体阳性。
  • 主要终点:第169天ESSDAI较基线的平均变化。
  • 关键次要终点:第169天ESSPRI和刺激全唾液流率较基线的平均变化。

临床怎么用

  • 不推荐阿巴西普用于中重度活动性pSS的常规治疗以改善临床结局。
  • 阿巴西普虽显示生物学活性,但未转化为临床获益,决策需结合个体情况。

局限性

  • 生物标志物和细胞亚群差异为事后分析,需谨慎解读。
  • 开放标签延伸期结果未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate efficacy and safety of abatacept in adults with active primary Sjögren's syndrome (pSS) in a phase III, randomised, double-blind, placebo-controlled trial. METHODS: Eligible patients (moderate-to-severe pSS [2016 ACR/European League Against Rheumatism (EULAR) criteria], EULAR Sjögren's Syndrome Disease Activity Index [ESSDAI] ≥5, anti-SS-related antigen A/anti-Ro antibody positive) received weekly subcutaneous abatacept 125 mg or placebo for 169 days followed by an open-label extension to day 365. Primary endpoint was mean change from baseline in ESSDAI at day 169. Key secondary endpoints were mean change from baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) and stimulated whole salivary flow (SWSF) at day 169. Other secondary clinical endpoints included glandular functions and patient-reported outcomes. Selected biomarkers and immune cell phenotypes were examined. Safety was monitored. RESULTS: Of 187 patients randomised, 168 completed double-blind period and 165 continued into open-label period. Mean (SD) baseline ESSDAI and ESSPRI total scores were 9.4 (4.3) and 6.5 (2.0), respectively. Statistical significance was not reached for primary (ESSDAI -3.2 abatacept vs -3.7 placebo, p=0.442) or key secondary endpoints (ESSPRI, p=0.337; SWSF, p=0.584). No clinical benefit of abatacept over placebo at day 169 was seen with other clinical and PRO endpoints. Relative to baseline, abatacept was associated with significant differences vs placebo in some disease-relevant biomarkers (including IgG, IgA, IgM-rheumatoid factor) and pathogenic cell subpopulations (post hoc analyses). No new safety signals were identified. CONCLUSIONS: Abatacept treatment did not result in significant clinical efficacy compared with placebo in patients with moderate-to-severe pSS, despite evidence of biological activity.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Baer AN, Gottenberg JE, St Clair EW, et al. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial. Ann Rheum Dis. 2020. PMID: 33168545. doi:10.1136/annrheumdis-2020-218599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。